For Slamon, who serves as director of clinical and translational research at the UCLA Health Jonsson Comprehensive Cancer Center and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, the recognition arrives after more than four decades of work that fundamentally reorganized how oncologists think about tumors. In a statement accompanying the announcement, he emphasized the collective nature of the achievement. “I’m incredibly honored to receive the Albany Award, but I think the best award is the fact that we — and I say we because it was not just me alone, but a group of us working on this — saw that we made an impact on so many lives,” Slamon said.

The scientific insight at the heart of the award is deceptively simple in hindsight: cancers arising in the same organ are not necessarily the same disease. Before Slamon’s work, breast cancer was largely treated as a single entity, stratified mainly by how far it had spread and how the cells looked under a microscope. Slamon’s team helped establish that tumors in the same organ can be biologically distinct diseases, each propelled by different molecular changes. That reframing has since become one of the organizing principles of modern oncology, underpinning the entire field of precision medicine in cancer care.

The specific discovery that changed everything involved a gene called HER2, which plays a role in regulating cell growth. Slamon’s laboratory found that roughly 20 percent of breast cancers contained multiple copies of this gene, a genetic amplification that floods the cell with growth-signaling machinery. Patients whose tumors carried this alteration tended to have more aggressive disease and poorer outcomes, a correlation that at first seemed to make HER2 merely a grim prognostic marker. But Slamon and his colleagues pushed the analysis further, demonstrating that HER2 was not simply a passive flag of aggressive disease — it was actively helping to drive tumor growth. That distinction transformed HER2 from a statistical indicator into a therapeutic target.

Turning that target into a drug required persistence in the face of considerable skepticism. Slamon and his collaborators began testing antibodies designed to latch onto the HER2 protein on the surface of cancer cells, an approach that many in the field doubted because previous attempts to use antibodies against cancer had largely failed. The laboratory evidence, however, kept pointing in the same direction: blocking HER2 could inhibit tumor growth. Working with scientists at Genentech, the team moved the strategy into human testing, with Slamon leading the first clinical trials of the antibody that would become known as Herceptin, conducted at UCLA. Those early studies showed that targeting HER2 with an antibody could produce a genuine clinical effect, and subsequent randomized trials demonstrated that adding Herceptin to standard treatment significantly improved outcomes for patients with HER2-positive breast cancer.

In 1998, the U.S. Food and Drug Administration approved Herceptin, and the consequences for patients were profound. HER2-positive breast cancer, once among the most aggressive and feared forms of the disease, became one of the breast cancers that can most often be treated successfully. Approximately 3.5 million women worldwide have now been treated with Herceptin for breast cancer, a figure that captures the scale of the translation from a chromosome abnormality identified in a laboratory to a therapy deployed across the globe. The success also validated a principle that has since reshaped drug development across oncology: identify the specific molecular change driving a tumor, and design a treatment against it.

Slamon and his colleagues did not stop with HER2. Applying the same logic of molecular targeting to other subtypes of the disease, their research helped demonstrate the effectiveness of CDK4/6 inhibitors — including palbociclib and ribociclib, marketed commercially as Ibrance and Kisqali — in hormone receptor-positive breast cancer. This subtype is the most common form of the disease, accounting for approximately 65 to 70 percent of breast cancers globally, which means the impact of this second line of research reaches an even larger patient population than the first. CDK4/6 inhibitors work by interfering with the cellular machinery that drives proliferation, effectively braking the cell division cycle that tumors depend upon, and the class has now become part of the standard of care for ER-positive breast cancer.

The reach of the original HER2 discovery has continued to expand in ways that extend well beyond breast cancer. HER2-targeted therapies are now used to treat other cancers driven by the same molecular alteration, and a newer generation of drugs known as antibody-drug conjugates builds directly on the approach Slamon pioneered. These engineered molecules use antibodies as delivery vehicles, homing in on tumor cells and releasing cancer-killing payloads more precisely than conventional chemotherapy, thereby concentrating toxicity where it is needed and sparing healthy tissue. It is a striking example of how a single mechanistic insight can keep generating clinical dividends decades after the initial discovery.

Leaders at UCLA framed the award as a testament to the kind of research the prize is designed to celebrate. “Dennis’ work represents the very best of what we strive to do in cancer research, taking discoveries made in the laboratory and translating them into treatments that fundamentally change patients’ lives,” said Dr. Michael Teitell, director of the UCLA Health Jonsson Comprehensive Cancer Center. “His pioneering research not only transformed the treatment of breast cancer but helped change how we understand and treat cancer more broadly. This recognition is incredibly well deserved.” The Albany Prize’s emphasis on translation — on the difficult, often unglamorous passage from bench discovery to approved therapy — makes Slamon’s career an almost archetypal case study of what that process demands.

Slamon’s work is not finished. He continues to investigate new antibody-based therapies and treatment combinations aimed at improving cancer control while reducing treatment-related side effects and preserving patients’ quality of life, a focus that reflects how survivorship has become a central consideration now that many targeted cancers are managed as chronic or curable disease. Over his more than 40-year career at UCLA, his contributions have already earned him some of the highest honors in medicine and oncology, including the Lasker-DeBakey Clinical Medical Research Award, the Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research, the Sjöberg Prize from the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation, the American Cancer Society’s Medal of Honor for Clinical Research, and the Canada Gairdner International Award. The 2026 Albany Prize adds another landmark to a career that helped prove a radical idea: that decoding the molecular wiring of a tumor is the surest path to defeating it.

Subject of Research: Award of the 2026 Albany Prize to Dr. Dennis Slamon for discoveries in HER2-targeted and CDK4/6 inhibitor breast cancer therapy

Article Title: Dr. Dennis Slamon awarded the 2026 Albany Prize for developing lifesaving cancer treatments

Article References: Dr. Dennis Slamon awarded the 2026 Albany Prize for developing lifesaving cancer treatments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Dennis Slamon, Albany Prize, HER2, Herceptin, breast cancer, targeted therapy, CDK4/6 inhibitors, palbociclib, ribociclib, UCLA, precision medicine, oncology

CDK4/6 inhibitors have revolutionized the landscape of breast cancer therapy by targeting critical cell cycle regulators, thus halting tumor cell proliferation. When combined with aromatase inhibitors—which reduce estrogen levels, a known driver for HR+ breast cancers—these drugs have substantially improved progression-free survival rates. Yet, until now, direct head-to-head comparisons among the four clinically approved CDK4/6 inhibitors—palbociclib, ribociclib, abemaciclib, and dalpiciclib—have been conspicuously absent, leaving oncologists reliant on indirect evidence and individual trial reports.

The present meta-analysis bridges this gap by applying fixed-effect consistency models to pooled data extracted from a systematic search of PubMed, Embase, and the Cochrane Library up to May 2024. This methodological framework allowed the researchers to generate a robust hierarchy of drug profiles, assessing key clinical outcomes such as progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR), and both all-grade and grade 3/4 adverse events (AEs).

Among the quartet of CDK4/6 inhibitors, dalpiciclib emerged as a frontrunner in maximizing progression-free survival, boasting a Surface Under the Cumulative Ranking (SUCRA) value of 77.9%. This metric suggests that patients treated with dalpiciclib plus AI therapy are likely to experience longer intervals without disease progression, offering a compelling clinical advantage. However, this efficacy comes at a cost, as dalpiciclib also registered the highest probabilities for both all-grade AEs and severe (grade 3/4) AEs, at 91.3% and an alarming 99.8%, respectively.

Conversely, abemaciclib distinguished itself in terms of response metrics, securing the top ranks for both ORR and CBR—89.3% and 68.9%, respectively. These indicators reflect the proportion of patients achieving significant tumor shrinkage or sustained clinical benefit, thus highlighting abemaciclib’s potent antitumor activity. Furthermore, subgroup analyses underscored abemaciclib’s superiority in prolonging PFS across diverse patient populations, reinforcing its versatility and therapeutic promise.

Safety profiles revealed an intricate balance between benefit and risk among the CDK4/6 inhibitors. Ribociclib demonstrated the lowest incidence of adverse events overall, presenting a safer option for patients who may be vulnerable to treatment-related toxicity. Interestingly, abemaciclib, despite its efficacy, had the lowest rate of severe adverse events among the four agents, suggesting a unique tolerability profile that might favor its use in certain clinical scenarios.

The study’s findings emphasize the absence of statistically significant differences in PFS among these inhibitors, which points to a nuanced therapeutic landscape where efficacy and safety must be carefully weighed. While dalpiciclib offers marginally superior control over disease progression, its heightened toxicity profile necessitates vigilant patient monitoring and may limit its suitability for some individuals.

These insights arrive at a crucial juncture as breast cancer treatment moves increasingly toward personalization. The ability to predict not only which drug will extend survival but also which regimen will minimize toxicity is instrumental in improving quality of life and clinical outcomes. Network meta-analyses like this one play a pivotal role in aggregating scattered data into actionable knowledge, guiding clinicians through the complexity of treatment choices.

It is particularly noteworthy that the absence of direct comparative randomized controlled trials (RCTs) has not impeded this analysis. Instead, innovative statistical modeling has enabled indirect comparisons that approximate real-world clinical scenarios, thereby enhancing the evidence base without waiting years for head-to-head trials to conclude. This methodological advance underscores the critical role of meta-research in precision oncology.

Moreover, this research highlights the importance of continuing pharmacovigilance and post-marketing surveillance, especially given the differential adverse event risks. Clinicians are reminded that therapeutic decisions in advanced breast cancer remain a balancing act, integrating tumor biology, patient comorbidities, and drug safety profiles.

Future investigations could extend these findings by integrating biomarker analyses to stratify patients who would benefit most from each CDK4/6 inhibitor. Additionally, exploring combination strategies, sequencing, and resistance mechanisms will be essential for harnessing the full potential of these targeted agents.

In sum, this comprehensive network meta-analysis offers a critical lens through which the four leading CDK4/6 inhibitors can be compared, delivering a sophisticated understanding of how each agent fares in efficacy and toxicity. Such knowledge not only enriches clinical guidelines but empowers oncologists and patients alike to make informed, personalized treatment choices in the fight against HR+/HER2- advanced breast cancer.

As the oncology community digests these findings, the message is clear: while no single CDK4/6 inhibitor outshines the others across all domains, nuanced differences in therapeutic benefit and safety profiles can now inform tailored approaches. Dalpiciclib’s robust PFS benefit positions it as a powerful option for patients with tolerable risk, whereas abemaciclib and ribociclib offer alternative balances of efficacy and safety.

This landmark analysis paves the way for an era of more strategic, evidence-driven use of CDK4/6 inhibitors, ultimately striving to transform clinical outcomes and patient experiences in advanced breast cancer management.

Subject of Research: Comparative efficacy and safety of first-line CDK4/6 inhibitors plus aromatase inhibitor therapy in HR+/HER2- advanced breast cancer

Article Title: Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis

Article References:
Kang, Y., Han, B., Kong, Y. et al. Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis. BMC Cancer 25, 843 (2025). https://doi.org/10.1186/s12885-025-14194-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14194-w